AI
| Followers | 842 |
| Posts | 122790 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Saturday, April 23, 2011 5:42:24 PM
ABT’s 1Q11 sales in emerging markets grew 38% year-over-year:
The 38% figure is somewhat artificial insofar as 2010 sales (but not 2009 sales) include the Solvay (#msg-41922225) and Piramal (#msg-50436738) acquisitions; however, even on an apples-to-apples basis, ABT’s 1Q11 sales in emerging markets grew more than 20% YoY.
Note the 117% growth in the Established Pharmaceuticals unit, which is where branded generics reside.
The 38% figure is somewhat artificial insofar as 2010 sales (but not 2009 sales) include the Solvay (#msg-41922225) and Piramal (#msg-50436738) acquisitions; however, even on an apples-to-apples basis, ABT’s 1Q11 sales in emerging markets grew more than 20% YoY.
Note the 117% growth in the Established Pharmaceuticals unit, which is where branded generics reside.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
